SQZ Biotechnologies downgraded to Neutral from Buy at H.C. Wainwright
The Fly

SQZ Biotechnologies downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar downgraded SQZ Biotechnologies to Neutral from Buy without a price target. The company’s "sizable" restructuring effort lead the analyst to shift expectations for data next week. The decision to announce a significant restructuring prior to the data announcement likely indicates that the data are not impressive, Bodnar tells investors in a research note. The analyst alsos believe the decision to pause both monotherapy and combination cohorts for the antigen presenting cells platform likely indicates that the data in combination were not materially better than the monotherapy data.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on SQZ:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App